Compare ACADIA Pharmaceuticals Inc. (ACAD) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs PepsiCo, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while PepsiCo, Inc. trades at $137.85 (market cap $188.91B). The key difference: PepsiCo, Inc. is far larger — about 37.3× ACADIA Pharmaceuticals Inc.'s market cap, and PepsiCo, Inc. pays a 4.28% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PEP | |
|---|---|---|
Market Cap | $5.07B | $188.91B |
Sector | Health | Consumer Staples |
52-Week High | $29.41 | $170.44 |
52-Week Low | $20.06 | $134.95 |
Enterprise Value | $4.19B | $231.41B |
Dividend Yield | — | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PepsiCo (PEP) trades at $137.69, down 0.95% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company maintains strong fundamentals with $93.93B revenue in 2025, 10.78% net margin, and consistent dividend payments. Recent news highlights price adjustments for snack products and sponsorship withdrawals, while analysts project 15% upside to the $158.79 consensus target.
PepsiCo presents a mixed outlook with solid fundamentals and dividend yield offset by near-term price pressure and competitive challenges. The stock offers value at current levels for income investors, though execution risks in North America and consumer pricing sensitivity require monitoring. Wall Street maintains cautious optimism with 64% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
